This transmission electron microscope image shows SARS-CoV-2, the virus that causes COVID-19. Credit: NIAID-RML.

Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates

Follow the latest updates of the outbreak on our timeline.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Inovio Pharmaceuticals has received a $5m grant from the Bill & Melinda Gates Foundation to support the testing and scale-up of a smart delivery device for Covid-19 vaccine, INO-4800.

Currently, INO-4800 is in preclinical studies and expected to enter clinical trials in the US in April.

The company previously received funding from the Coalition for Epidemic Preparedness Innovations (CEPI) to support preclinical and initial clinical development of the vaccine candidate.

Inovio intends to expedite the scale-up of the CELLECTRA 3PSP devices for large scale manufacturing of INO-4800 doses by the end of this year.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

CELLECTRA 3PSP is a small, portable, hand-held device that requires AA batteries, facilitating stockpiling without maintenance.

The company’s device manufacturing facility in San Diego will generate initial quantities and validate the design and scale-up of manufacturing processes, later contracted to other manufacturers for increased capacity.

Inovio Pharmaceuticals president and CEO Joseph Kim said: “Inovio is grateful to the Bill & Melinda Gates Foundation for their continued investment in Inovio’s DNA medicines platform and for their support for DNA vaccines to potentially protect those at risk globally given the current Covid-19 outbreak.

“Our team of vaccine experts are working around the clock to advance INO-4800 and we look forward to attracting additional partnerships to expedite its development to meet this urgent global health need.”

Earlier this month, the company accelerated its timeline for the development of a Covid-19 vaccine.